27 de Junio, 2023
16 de Enero, 2024
11:59 PM
Development and proof of principle of new clinical applications of theranostics solutions-HORIZON-JU-IHI-2023-05-02
Investigación / Innovación
Escuela de Medicina y Ciencias de la Salud
Comisión Europea
10 000 000 - 12 000 000 EUR
Project(s) funded under this topic should aim at developing new, or innovative combinations of existing multi-modal theranostic solutions including radiopharmaceuticals and/or non- radioactive theranostic solutions. Applicants should clearly identify a disease(s) of unmet public health need, (e.g., oncology, neurology and/or advanced multi-disease conditions) and explain their choice with relevant evidence where possible.
ExpectedOutcome:
Research and innovation (R&I) actions to be supported under this topic must contribute to at least three of the following outcomes:
1,Patients will benefit from increased treatment efficacy, reduction of time-to-treat, fewer side effects, and reduced duration of hospitalisation.
2,Healthcare professionals benefit from education, training on theranostic treatment approaches, recommendations, and clinical guidelines on the most appropriate use of theranostic solutions.
3,European healthcare systems benefit from a broader spectrum of theranostic treatments and improved cost-effectiveness and affordability of theranostic solutions due to scale effects and more robust European supply chains.
4,Technology developers, healthcare professionals and patients benefit from increased information on the sensitivity, quantification, stratification and staging of diseases.
Expected Impact:
•Improved availability of effective treatments for patients based on multi-modal theranostic1 solutions.
•Stronger resilience and improved strategic autonomy of Europe’s health systems, for example, by implementing new manufacturing capabilities for medical radioisotopes and radiopharmaceuticals (in accordance with the EU SAMIRA2 action plan).
•Depending on the disease area of the application, contributing to the objectives of Europe's Beating Cancer Plan and the Horizon Europe Mission on Cancer.
Documents: (Check them on the webside).
IHI JU Evaluation form for Research and Innovation Actions (single and two-stage Calls)
IHI JU Proposal template (RIA/SP) - Part B
•Colombia is eligible as a third country, for this it must participate with the role of partner together with a consortium with at least three entities from different European/associated countries).
OBJETIVO/DESCRIPCIÓN
Project(s) funded under this topic should aim at developing new, or innovative combinations of existing multi-modal theranostic solutions including radiopharmaceuticals and/or non- radioactive theranostic solutions. Applicants should clearly identify a disease(s) of unmet public health need, (e.g., oncology, neurology and/or advanced multi-disease conditions) and explain their choice with relevant evidence where possible.
REQUISITOS CLAVE
ExpectedOutcome:
Research and innovation (R&I) actions to be supported under this topic must contribute to at least three of the following outcomes:
1,Patients will benefit from increased treatment efficacy, reduction of time-to-treat, fewer side effects, and reduced duration of hospitalisation.
2,Healthcare professionals benefit from education, training on theranostic treatment approaches, recommendations, and clinical guidelines on the most appropriate use of theranostic solutions.
3,European healthcare systems benefit from a broader spectrum of theranostic treatments and improved cost-effectiveness and affordability of theranostic solutions due to scale effects and more robust European supply chains.
4,Technology developers, healthcare professionals and patients benefit from increased information on the sensitivity, quantification, stratification and staging of diseases.
Expected Impact:
•Improved availability of effective treatments for patients based on multi-modal theranostic1 solutions.
•Stronger resilience and improved strategic autonomy of Europe’s health systems, for example, by implementing new manufacturing capabilities for medical radioisotopes and radiopharmaceuticals (in accordance with the EU SAMIRA2 action plan).
•Depending on the disease area of the application, contributing to the objectives of Europe's Beating Cancer Plan and the Horizon Europe Mission on Cancer.
Documents: (Check them on the webside).
IHI JU Evaluation form for Research and Innovation Actions (single and two-stage Calls)
IHI JU Proposal template (RIA/SP) - Part B
•Colombia is eligible as a third country, for this it must participate with the role of partner together with a consortium with at least three entities from different European/associated countries).